+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zydus Cadila - logo

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

From
Bevacizumab - Biosimilars Insight, 2020 - Product Thumbnail Image

Bevacizumab - Biosimilars Insight, 2020

  • Report
  • August 2020
  • 125 pages
From
Levofloxacin Market - Product Thumbnail Image

Levofloxacin Market

  • Report
  • August 2020
  • 122 pages
From
From
Adalimumab - Biosimilar Insight, 2021 - Product Thumbnail Image

Adalimumab - Biosimilar Insight, 2021

  • Drug Pipelines
  • May 2021
  • 120 Pages
From
Humira Biosimilars Clinical Trial Insight - Product Thumbnail Image

Humira Biosimilars Clinical Trial Insight

  • Clinical Trials
  • October 2016
  • 80 Pages
From
From
PDE Inhibitors Market, 2016-2026 - Product Thumbnail Image

PDE Inhibitors Market, 2016-2026

  • Report
  • October 2016
  • 223 Pages
From
From
From
From
From
Global Generic Drugs Market 2020-2025 - Product Thumbnail Image

Global Generic Drugs Market 2020-2025

  • Report
  • May 2021
  • 155 Pages
From
From
Loading Indicator
adroll